Overview MDPK67b in Patients With Prostate Cancer Status: Recruiting Trial end date: 2023-08-31 Target enrollment: Participant gender: Summary Administration of MDPK67b to assess its Tolerability and Safety profile in prostate cancer patients, and to assess histo-pathological and molecular changes in prostate tumor tissue samples. Phase: Phase 1 Details Lead Sponsor: Med Discovery SACollaborators: Camara and Partners SàrlSoladis